Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adolescents
2018-000326-58Phase 3Terminated
- Sponsor
- Aimmune Therapeutics, Inc.
- Start
- Jun 2018
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of peanut protein in peanut allergy and food allergy (2 arms), sponsored by Aimmune Therapeutics, Inc. Primary endpoint: Health-related quality of life (HRQOL). Started Jun 2018; status: terminated.
02
Drugs
peanut protein
03
Conditions
peanut allergyfood allergy
Beyond the preview
Go deeper on 2018-000326-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000326-58.